Table 1.
Clinical-pathological Features, Immunohistochemical Markers and Outcome in Studied Patients with NHL.
| Characteristics | All patients (N=90) | |||
|---|---|---|---|---|
| No. | (%) | |||
| Age | Mean ± SD | 57.82 ±14.11 | ||
| (Years) | Median (Range) | 58 (25-90) | ||
| Sex | Male | 49 | (54.4) | |
| Female | 41 | (45.6) | ||
| Extranodal involvement | ||||
| Absent | 64 | (71.1) | ||
| Present | 26 | (28.9) | ||
| Stage | Stage I | 14 | (15.6) | |
| Stage II | 25 | (27.8) | ||
| Stage III | 35 | (38.9) | ||
| Stage IV | 16 | (17.8) | ||
| IPI risk group | Low | 14 | (15.6) | |
| Low-Intermediate | 23 | (25.6) | ||
| High-Intermediate | 33 | (36.7) | ||
| High | 20 | (22.2) | ||
| Response | PD | 27 | -30 | |
| SD | 15 | (16.7) | ||
| PR | 28 | (31.1) | ||
| CR | 20 | (22.2) | ||
| OAR | 48 | (53.3) | ||
| NR | 42 | (46.7) | ||
| *Follow-up | Mean ± SD | 24.78 ±9.38 | ||
| Median (Range) | 29 (4-36) | |||
| Relapse | (N=20) | |||
| Before 24 month | 8 | -40 | ||
| After 24 month | 12 | -60 | ||
| Progression | (N=42) | |||
| Within 6 month | 30 | (71.4) | ||
| After 6 month | 12 | (28.6) | ||
| Mortality | A live | 66 | (73.3) | |
| Died | 24 | (26.7) | ||
| Ki 67 | Low | 23 | (25.6) | |
| High | 67 | (74.4) | ||
| BCL2 | Negative | 48 | (53.3) | |
| Positive | 42 | (46.7) | ||
| MYC | Negative | 58 | (64.4) | |
| Positive | 32 | (35.6) | ||
| Co-expression | Non-expressor | 43 | (47.8) | |
| BCL2 expressor | 15 | (16.6) | ||
| MYC expressor | 5 | (5.6) | ||
| Double expressor | 27 | (30) | ||
| Bouble hit | Absent | 83 | (92.2) | |
| Present | 7 | (7.8) | ||